Compare PCYO & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCYO | AVXL |
|---|---|---|
| Founded | 1976 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 242.8M | 251.1M |
| IPO Year | 1995 | 2013 |
| Metric | PCYO | AVXL |
|---|---|---|
| Price | $10.43 | $3.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 50.2K | ★ 943.0K |
| Earning Date | 04-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.50 | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $1,227,787.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $46.35 | ★ N/A |
| Revenue Growth | ★ 171.54 | N/A |
| 52 Week Low | $9.65 | $2.61 |
| 52 Week High | $12.44 | $13.99 |
| Indicator | PCYO | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 43.68 | 48.02 |
| Support Level | $9.85 | $2.93 |
| Resistance Level | $10.97 | $3.50 |
| Average True Range (ATR) | 0.46 | 0.17 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 25.28 | 51.03 |
Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in three business segments namely Water and wastewater resource development, Land development, and the Single-Family Rental Segment. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.